Trial · NCT07112365
The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
NCT07112365, Phase 4, Recruiting, The University of Texas Health Science Center, Houston
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project. Trials, record NCT07112365. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07112365
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
- NCT number
- NCT07112365
- Status
- Recruiting
- Phases
- Phase 4
- Enrollment
- 25 participants, estimated
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Dravet Syndrome
- Interventions
- Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct)
- First posted
- 2025-08-08
- Last updated
- 2026-07-15
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in blood oxygenation level in response to CO₂ | Baseline, Day ~60 | Measures how much blood oxygenation level dependent (BOLD) signal changes in response to CO₂, using fMRI. |
| Primary | Change in speed of cerebrovascular response to CO₂ | Baseline, Day ~60 | Measures how quickly the brain responds to CO₂ exposure during fMRI. |
| Secondary | Change in breathing response to CO₂ | Baseline, Day ~60 | Assesses how the participant's breathing rate changes when CO₂ levels are increased. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07112365
GET https://conductscience.org/api/trials/v1/NCT07112365/registered